SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-210639
Filing Date
2022-08-03
Accepted
2022-08-03 08:17:02
Documents
13
Period of Report
2022-07-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d384456d8k.htm   iXBRL 8-K 29650
2 EX-99.1 d384456dex991.htm EX-99.1 11358
  Complete submission text file 0001193125-22-210639.txt   166229

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA amrx-20220729.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE amrx-20220729_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE amrx-20220729_pre.xml EX-101.PRE 10811
7 EXTRACTED XBRL INSTANCE DOCUMENT d384456d8k_htm.xml XML 3244
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 221131010
SIC: 2834 Pharmaceutical Preparations